Results 21 to 30 of about 752,420 (346)

Matrix Metalloproteinase-9 and Inflammation in Different Types of Multiple Sclerosis [PDF]

, 2016
Different clinical courses of multiple sclerosis, heterogeneity of its clinical implications, different effect of immunomodulatory therapy for the same clinical forms implies various pathogenetic mechanisms of central nervous system damage at this ...
Chernenko, M. (Maksym), Nehreba, T. (Tatyana), Vasylovskyy, V. (Vitaliy), Voloshyna, N. (Nataliya), Vovk, V. (Viktoriya)   +4 more
core   +2 more sources

A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [PDF]

, 2002
Background: In patients with isolated syndromes that are clinically suggestive of multiple sclerosis, such as optic neuritis or brain-stem or spinal cord syndromes, the presence of lesions as determined by T2-weighted magnetic resonance imaging (MRI) of ...
Brex, P.A., Ciccarelli, O., Miller, D.H., O'Riordan, J.I., Sailer, M., Thompson, A.J.   +5 more
core   +1 more source

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]

, 2010
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Bartholomaus I., Ben-Nun A., Bennett JL, Bielekova B., Bradl M., Chabas D., De Jager PL, De Jager PL, Dornmair K., Ferguson B., Flügel A., Frischer JM, Gold R., Gregersen JW, Han MH, Hohlfeld R., Hohlfeld R., Junker A., Kerschensteiner M., Kerschensteiner M., Kinoshita M., Korn T., Krishnamoorthy G., Kuhlmann T., Kümpfel T., Kümpfel T., Kümpfel T., Lennon VA, Linington C., Lock C., Mathey EK, Misgeld T., Platten M., Pollinger B., Polman CH, Reinhard Hohlfeld, Schluesener HJ, Seitz S., Sobottka B., Stadelmann C., Trapp BD, Trapp BD, Wiendl H., Wiendl H., Zipp F.   +44 more
core   +1 more source

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity

Journal of Patient Experience, 2021
Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS, Ellen O’Donnell PhD, Katia Canenguez PhD, EdM, Paola B Castro-Mendoza BSc, MSc, Tim Lotze MD, Emmanuelle Waubant MD, PhD, Bianca Weinstock-Guttmann MD, Tanuja Chitnis MD   +7 more
doaj   +1 more source

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Frontiers in Neurology, 2023
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto   +7 more
doaj   +1 more source

Concurrent TNFRSF1A R92Q and pyrin E230K mutations in a child with multiple sclerosis [PDF]

, 2010
We report a 16-year-old female patient with a severe course of multiple sclerosis and concomitant symptoms suggestive of a hereditary autoinflammatory disease.
Blaschek, Astrid, Borggraefe, I., Heinen, F., Hohlfeld, R., Huss, K., Kümpfel, T., Lohse, P., Mueller-Felber, W.   +7 more
core   +1 more source

Multiple sclerosis

Disease-a-Month, 1996
Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature. The cause is unknown; both genetic and environmental factors have been implicated in the pathogenesis. MS generally presents with the acute or subacute onset of neurologic
Lynch, Sharon G., Rose, John W.
openaire   +2 more sources

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

Nature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination [PDF]

, 2017
Remyelination is in the center of new therapies for the treatment of multiple sclerosis to resolve and improve disease symptoms and protect axons from further damage.
Bramlett, Brück, Brück, Clark, Cunningham, Foote, Fünfschilling, Gudi, Hiremath, Hiremath, Irvine, Irvine, Kornek, Kuhlmann, Kutzelnigg, Lassmann, Lassmann, Lee, Lindner, Lindner, Lucchinetti, Manrique-Hoyos, Mason, Matsushima, McKenzie, Mildner, Morrison, Murray, Nikic, Otsuka, Patrikios, Pierce, Schuh, Simons, Singh, Skripuletz, Sorbara, Stidworthy, Trapp   +38 more
core   +1 more source